Covered recipient · General Payments record
MANDANA SHAFAI
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$810.10
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $379.25 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $96.15 | 4 |
| Novo Nordisk AS | $71.17 | 3 |
| Astellas Pharma US Inc | $66.28 | 3 |
| Bausch Health US, LLC | $47.71 | 3 |
| PFIZER INC. | $36.16 | 2 |
| Lilly USA, LLC | $23.41 | 1 |
| Acerta Pharma LLC | $22.11 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $16.26 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.87 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106061178 | CMS |
| ABBVIE INC. | $18.53 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106061180 | CMS |
| ABBVIE INC. | $33.03 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106061182 | CMS |
| ABBVIE INC. | $30.72 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106061184 | CMS |
| Astellas Pharma US Inc | $22.68 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139320472 | CMS |
| Astellas Pharma US Inc | $23.40 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139401555 | CMS |
| Astellas Pharma US Inc | $20.20 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139444478 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.11 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105768902 | CMS |
| Bausch Health US, LLC | $13.71 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148021784 | CMS |
| Bausch Health US, LLC | $15.24 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148021786 | CMS |
| Bausch Health US, LLC | $18.76 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148021788 | CMS |
| Lilly USA, LLC | $23.41 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135163609 | CMS |
| Novartis Pharmaceuticals Corporation | $16.26 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087337667 | CMS |
| Novo Nordisk Inc | $22.01 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097055586 | CMS |
| Novo Nordisk Inc | $20.01 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097221379 | CMS |
| Novo Nordisk Inc | $29.15 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096592380 | CMS |
| PFIZER INC. | $15.60 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131739672 | CMS |
| PFIZER INC. | $20.56 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131042572 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.